Posters at Cancer Immunotherapy Conference

RNS Number : 6889N

Scancell Holdings Plc

26 September 2019

 

26 September 2019

Scancell Holdings plc

("Scancell" or the "Company")

Scancell to present six posters at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

Scancell, the developer of novel immunotherapies for the treatment of cancer, will be presenting at the 5^th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, being held at the Espace Grande Arche de la Defense in Paris, France, from 25-28 September 2019.

The 2019 meeting hosted by the Cancer Research Institute (CRI), the Association for Cancer lmmunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) will focus on "Translating Science into Survival," and feature talks from more than 50 leaders in the field covering all areas of inquiry in cancer immunology and immunotherapy.

Starting today, Professor Lindy Durrant, Ph.D., Chief Scientific Officer of Scancell and Professor of Cancer Immunotherapy at the University of Nottingham, and members of her research team will be presenting six posters, including one on FG2811 a new ultra-specific antibody with the ability to induce human stem memory T cell (TSCM) proliferation and differentiation. TSCM cells are a rare subset of white blood cells with the stem cell-like ability to self-renew and have capacity to differentiate into other T cell subsets that proliferate and accelerate anti-tumour immunity. Therefore, FG2811 has the potential to be utilised in vivo for cancer immunotherapy or to provide cells for CAR-T or TCR adoptive cell therapies.

The additional poster presentations contribute to the continued scientific understanding of Scancell's cancer immunotherapy platform, Moditope®, targeting stress induced post translational modifications (siPTMs). These data are important validators as Scancell advances the lead Moditope programme, Modi-1, towards the clinic and also to the continued preclinical advancement of Modi-2.

The poster presentations are as follows:

·      "An ultraspecific monoclonal antibody (FG2811) recognises a novel marker on stem memory T cells and induces cell proliferation and differentiation in vitro and in vivo" by Scancell, Nottingham University and Josep Carreras Leukaemia Research Institute

·      "Post-translationally modified antigens are good targets for cancer immunotherapy but some patients have antigen specific T-regs that may need to be neutralized" by Nottingham University and Scancell

·      "Improving selection criteria for post translationally modified CD4 epitopes using computer algorithms" by Scancell and Nottingham University

·      "Carbamylation of lysine residues mediated by MDSCs in the tumour environment make excellent targets for CD4 T cell mediated cancer immunotherapy" by Scancell, Nottingham University and Nottingham Trent University

·      "Targeting citrullinated vimentin and enolase with cytotoxic CD4 T cells relies upon MHC-II expression by tumors, reduces myeloid suppressor cells and directly kills tumor cells" by Scancell, ISA Pharmaceuticals and Nottingham University

·      "Citrullinated glucose-regulated protein 78 is a candidate target for cancer immunotherapy" by Scancell and Nottingham University

All posters will be made available on the Company's website, at https://www.scancell.co.uk/scientific-papers-posters 

For Further Information:

Scancell Holdings plc
Dr John Chiplin, Chairman		[phone]
Dr Cliff Holloway, CEO
Panmure Gordon (UK) Limited (Nominated Adviser and Corporate broker)
Freddy Crossley/Emma Earl		[phone]
FTI Consulting Simon Conway/Natalie Garland-Collins		[phone]

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody®, Moditope® and AvidiMab™ technology platforms.

ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system. They have the potential to be used as monotherapy or in combination with checkpoint inhibitors and other agents. This platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.

·      SCIB1, the lead programme, is being developed for the treatment of melanoma. A phase 1/2 clinical trial has so far successfully demonstrated survival data of more than five years.

·      SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumours. Scancell has entered into a clinical development partnership with Cancer Research UK (CRUK) for SCIB2.

Moditope® represents a completely new class of potent and selective immunotherapy agents based on stress-induced post-translational modifications (siPTM). It stimulates the production of killer CD4 T cells which overcome the immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. Moditope® alone, or in combination with other agents, has the potential to treat a wide variety of cancers.

·      Modi-1 is being developed for the treatment of solid tumours including triple negative breast cancer, ovarian cancer and head and neck cancer.

AvidiMab™ is a patent protected technology platform which increases the avidity of human antibodies by promoting non-covalent Fc-Fc interactions. This modification induces the direct tumour cell killing properties of Scancell's anti-glycan monoclonal antibodies (mAbs) but has broad potential to increase the avidity or potency of any therapeutic monoclonal antibody including those being developed for autoimmune diseases, as well as cancer.

For further details, please see our website:  www.scancell.co.uk

 

END

 

 

MSCEELFLKKFEBBZ